APLS Stock Analysis: Buy, Sell, or Hold?
APLS - Apellis Pharmaceuticals, Inc. Common Stock
$17.09
0.12 (0.71%)
▲
5d:
-2.73%
30d:
-18.46%
90d:
-31.56%
BUY
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Get Alerted When APLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: APLS shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: APLS shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: APLS is currently trading at $17.09, which is considered oversold relative to its 30-day fair value range of $17.72 to $21.27. From a valuation perspective, the stock is trading at a discount (Forward PE: -66.8) compared to its historical average (480.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, APLS is in a strong uptrend. The price is currently testing key support at $16.83. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: APLS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $33.40 (+95.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, APLS is in a strong uptrend. The price is currently testing key support at $16.83. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: APLS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $33.40 (+95.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$17.72 -
$21.27
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 95.4% below Wall St target ($33.40)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Fair Price Analysis
30-Day Fair Range
$17.72 -
$21.27
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$16.83
Resistance Level
$19.32
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-66.76
Wall Street Target
$33.40
(+95.4%)
Revenue Growth (YoY)
-5.9%
Profit Margin
2.2%
PE vs Historical
-66.8 vs 480.9
CHEAP
Share & Embed Analysis
Last updated: March 31, 2026 4:56 AM ET
Data refreshes hourly during market hours. Next update: 5:56 AM
Data refreshes hourly during market hours. Next update: 5:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is APLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Mark Jeffrey Delong
SELL
368 shares
2026-02-11
Caroline Baumal
SELL
2797 shares
2026-01-22
Timothy Eugene Sullivan
SELL
10287 shares
2026-01-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 54 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 51 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 50 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 44 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 54 HOLD |
